HSA
DNTH icon

Hussman Strategic Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Hussman Strategic Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,000
Closed -$630K – 238
2024
Q1 		$630K Buy
+21,000
New +$456K 0.15% 174

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Hussman Strategic Advisors's DNTH Position: Q2 2024 in Review

Hussman Strategic Advisors sold out of Dianthus Therapeutics (DNTH) in Q2 2024, closing a stake of 21,000 shares — an estimated $630K sold.

Hussman Strategic Advisors first reported a position in DNTH in Q1 2024 and held it in 1 quarter. The position peaked at $630K in Q1 2024. 74 funds tracked by Wall St. Rank hold DNTH as of Q2 2024.

  • Hussman Strategic Advisors reported no remaining Dianthus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Hussman Strategic Advisors sold 21,000 Dianthus Therapeutics shares in Q2 2024, an estimated $630K.
  • Hussman Strategic Advisors first reported a position in Dianthus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Hussman Strategic Advisors's Dianthus Therapeutics position peaked at $630K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2024.

Based on Hussman Strategic Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.